Buy anti-Vaccinia Virus A27L Protein antibody, Vaccinia Virus A27L Protein Monoclonal Antibody (Clone B1496M) (MBS313199) product datasheet at MyBioSource, Primary Antibodies. Application: ELISA (EIA), Immunofluorescence (IF)
Mouse Anti-Herpes Simplex Virus 1 HSV-1 gE Envelope Protein Monoclonal Antibody, Unconjugated, Clone 9H3 from Santa Cruz Biotechnology, Inc.,HSV-1 gE Envelope Protein (9H3),biological,biology supply,biology supplies,biology product
TY - JOUR. T1 - A novel activating anti-β1 integrin monoclonal antibody binds to the cysteine-rich repeats in the β1 chain. AU - Faull, Randall J.. AU - Wang, Jian. AU - Leavesley, David I.. AU - Puzon, Wilma. AU - Russ, Graeme R.. AU - Vestweber, Dietmar. AU - Takada, Yoshikazu. PY - 1996. Y1 - 1996. N2 - The functional status of an integrin depends on the conformation of its extracellular domain, which is controlled by the cell expressing that receptor. The transmission of regulatory signals from within the cell is considered to be via propagated conformational changes from the receptors cytoplasmic tails to the extracellular ligand binding pocket. The end result is increased accessibility of the ligand binding pocket in the high affinity (active) form of integrins. We report a novel monoclonal antibody (QE.2E5) that binds within the cysteine-rich repeats in the integrin β1 chain and induces high affinity binding of fibronectin to the integrin α5β1. The QE.2E5 epitope is located ...
• We recently produced the monoclonal antibody E48 as a specific reagent for squamous cell carcinomas. In our ongoing investigations to use E48 for clinical tum
Mouse Monoclonal Anti-Human BCL-10 (B Cell Lymphoma) Antibodies MA-20003 Mouse Monoclonal Anti-Human BCL-10 (B Cell Lymphoma) Antibodies MA-20003
... ,This antibody detects an ~92 kDa protein corresponding to the apparent molecular mass of the beta subunit of Hypoxia Inducible Factor-1 (HIF-1beta) on Western blots.,biological,biology supply,biology supplies,biology product
Monoclonal Antibody (mAB) Therapy is a type of immunotherapy. It employs specific antibodies to target cancer cells for removal from the body. This type of therapy relies on the bodys own immune system to fight the cancer, rather than attacking the cells with damaging chemotherapy and radiation.. To understand how this therapy works, you must understand what antigens and antibodies are. Antigens are cell markers that are produced in every type of cell - the cells of your body, bacteria, and viruses. These markers are different in every cell type, so your body can tell them apart. Antibodies are designed to bind to antigens, like fitting two puzzle pieces together. Monoclonal antibodies are large groups of antibodies that only bind to one antigen.. In monoclonal antibody therapy, doctors inject patients with antibodies that bind to the antigens on cancer cells. In this way, they are "tagging" the bad cells. When cells are tagged with these antibodies, they are marked for removal by immune cells. ...
Using immunoblotting techniques, the antigen that binds the monoclonal antibody M27 has been clearly defined in terms of apparent molecular mass and distribution. In reducing conditions it has an apparent mass of 178K (K = 10(3) Mr) and is present in the cytoplasm and membranes of all mammalian tissue culture cells so far examined. It is absent from lines derived from avian, piscine and amphibian sources. It is also absent from foetal liver of both rat and mouse, but subsequently appears after cultivation in vitro. Similarly, it can be detected on rat lymphocytes only after mitogenic stimulation. However, it is found on both hepatoma and lymphoma cells in vitro, and on in vivo tumours from murine sources. It thus appears to be associated with cell proliferation. ...
Buy anti-CD11b antibody, Rat CD11b Monoclonal Antibody (Clone M1/70.15)-P05555.2 (MBS210514) product datasheet at MyBioSource, Primary Antibodies. Application: Flow cytometry (FC/FACS)
Rabbit monoclonal antibody raised against a human PDGFA peptide using ARM Technology. A synthetic peptide of human PDGFA is used for rabbit immunization.Customer or Abnova will decide on the preferred peptide sequence. (H00005154-K) - Products - Abnova
The rat IgG2a isotype control antibody clone ES26-15B7.3 is specific for keyhole limpet hemocyanin (KLH). This protein is not expressed on mammalian cells or cell lines. Therefore, the antibody clone ES26-15B7.3 can be used as a negative control to distinguish specific from non-specific binding of rat IgG2a fluorochrome-conjugated antibodies to human and mouse cells, for example, via Fc receptors, or due to interactions of the fluorochrome with the cell surface. - 대한민국
Read Therapeutic Monoclonal Antibodies From Bench to Clinic by with Rakuten Kobo. 70-chapter authoritative reference that covers therapeutic monoclonal antibody discovery, development, and clinical app...
Anti-Human Angiotensin I Antibody, clone Ang E9 (BGN/KA/4H) , Mouse Anti-Human Monoclonal Antibody validated in E (ABD10296), Abgent
Characterization of aggregation information of monoclonal antibodies (mAb) is gaining importance because an increasing number of mAb-based therapeutics are entering clinical studies and gaining marketing approval. dye concentration. Inset: Double reciprocal representation.20 (B) Temperature-dependence of mAb unfolding studied with ANS binding. Dye binding rates were decided … We also measured kinetic rates of the conformational change of monomer at the PD98059 elevated temperatures (Desk 1) with an empirical sigmoid function suit through the ANS fluorescence modification (see Supporting Details) (Fig. 2B). The mAb was incubated at raised temperature ranges (63C70C) at 0.2 mg/mL concentrations up to 6 h and 20 M ANS was added soon after the incubation, held in ice drinking water for 2 h. The aggregate amounts in these biopharmaceuticals are usually suprisingly low during long-term storage space conditions also at high proteins concentrations. We examined the aggregate amounts at different mAb ...
TY - JOUR. T1 - The antitumor monoclonal antibody MOv2 recognizes the Lewis A hapten. AU - Leoni, F.. AU - Magnani, J. L.. AU - Miotti, S.. AU - Canevari, S.. AU - Pasquali, M.. AU - Sonnino, S.. AU - Colnaghi, M. I.. PY - 1988. Y1 - 1988. N2 - Monoclonal antibody MOv2, produced against ovarian carcinoma, was previously found to bind a carbohydrate epitope (CAMOv2) present on mucins, glycoproteins and a neutral glycolipid. In this paper, the structure of the carbohydrate epitope is determined by immunological reactivity with purified glycolipids and oligosaccharides. Using solid-phase radioimmunoassay and immunostaining of thin layer chromatograms, MOv2 binds strongly to Le(a)-active pentasaccharide ceramide. A smaller neutral glycolipid also weakly binds MOv2. Fifty percent inhibition of binding to Le(a)-active pentasaccharide ceramide is achieved with approximately 8 μM concentration of lacto-N-fucopentaose II (LNF II). Lacto-N-tetraose (LNT) also partially inhibits at about 103 times higher ...
... - This antibody only binds prorenin. It does not bind renin and blocks prorenin activation.
Monoclonal antibodies are a unique class of biological agents that have been developed for autoimmune disease, antitumor and antiplatelet therapy to name a few. Antibodies produced by the body in response to an infection are polyclonal antibodies, meaning the antibodies produced are not identical. Monoclonal antibodies are immunoglobulins that are identical and bind to the same antigenic surface marker, thus the term targeted therapy. The naming of monoclonal antibodies is based on the target of the antibody (e.g. tumor, viral) and the source from which the antibody was produced (e.g. murine, human), followed by the "mab" suffix. While monoclonal antibodies have a wide therapeutic benefit, they have limitations including inability to cross the blood brain barrier and cost.. This presentation will review the history, types and immunogenicity of each type of monoclonal antibody. The nurse will understand the naming nomenclature of monoclonal antibodies and will be able to recognize the action of ...
Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs ...
Discover singular and custom rat monoclonal antibodies of higher sensitivity and higher affinity! Rat monoclonal antibodies against hormones, peptides, steroids, toxins, DNA, RNA.
Heparan Sulfate Proteoglycan (Large) / Perlecan Antibody, Rat Monoclonal Antibody [Clone SPM255 ] validated in IHC, IF, FC (AH11473-7), Abgent
Rat anti-Mouse IgG1, eFluor 660, clone: M1-14D12, Secondary Antibody, eBioscience™ 100μg; eFluor 660 Rat anti-Mouse IgG1, eFluor 660, clone: M1-14D12,...
Serum levels of HAHAs were detected by a newly developed radioimmunoassay, a specific assay measuring high avid antibodies against adalimumab, similar to that described for rituximab.4. HAHAs were present after cessation of treatment for the planned surgical procedure, whereas serum levels of adalimumab were undetectable (fig 1). As levels of HAHAs increased, levels of adalimumab dropped and disease activity increased.. Our patient developed HAHAs to adalimumab despite the fact that adalimumab is a human monoclonal antibody. Infliximab is a chimeric antibody and can induce an immunogenic reaction in the form of human antichimeric antibodies. The development of HACAs to infliximab is associated with a reduced response to treatment,5 and so far such relationships have not been described for adalimumab.. In our patient, the anti-rheumatic drug-free period may have influenced the development of HAHAs. The absence of the protective role of methotrexate may have stimulated the formation of HAHAs. ...
Monoclonal antibodies on MOUSE Tissue - posted in Immunology: Heres a question for the ages..Does anyone have a CLUE as to whether a protocol exists to use mouse monoclonal antibodies on mouse tissues without the outrageous background staining?? All suggestions are welcome. Thanx.
A human IgG1 monoclonal antibody directed against interleukin-1 alpha (IL1a) with potential A human IgG1 monoclonal antibody targeting the inflammatory cytokine interleukin-1 alpha (IL1a) with potential antineoplastic, anti-cachectic and anti-angiogenic activities. Anti-IL1a monoclonal antibody MABp1 targets and binds to IL1a and prevents IL1a activity. This prevents IL1a-mediated tumorigenesis and angiogenesis. In addition, MABp1 abrogates IL1a-mediated cachexia. IL1a, an inflammatory mediator expressed on monocytes, platelets and overexpressed by certain tumors, plays a key role in the promotion of tumor cell growth, metastasis and invasion. In addition, IL1a stimulates metabolic activity in the central nervous system.
Objectives: Despite the therapeutic value of current rheumatoid arthritis (RA) treatments, agents with alternative modes of action are required. Mavrilimumab, a fully human monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor receptor-α, was evaluated in patients with moderate-to-severe RA. Methods: In a phase IIb study (NCT01706926), patients with inadequate response to ≥1 synthetic disease-modifying antirheumatic drug(s), Disease Activity Score 28 (DAS28)−C reactive protein (CRP)/erythrocyte sedimentation rate ≥3.2, ≥4 swollen joints despite methotrexate (MTX) were randomised 1:1:1:1 to subcutaneous mavrilimumab (150, 100, 30 mg), or placebo every other week (eow), plus MTX for 24 weeks. Coprimary outcomes were DAS28−CRP change from baseline to week 12 and American College of Rheumatology (ACR) 20 response rate (week 24). Results: 326 patients were randomised (150 mg, n=79; 100 mg, n=85; 30 mg, n=81; placebo, n=81); 305 completed the study (September ...
The most comprehensive custom mouse monoclonal antibody production services: custom production of monoclonal antibodies against non-modified, phospho-specific, methylation-specific, and acetylation-specific peptides and proteins; monoclonal antibodies for ELISA, Western blot, IP, IF, ICC, and IHC applications. Guaranteed ELISA > 1:40 000.
Rabbit monoclonal antibody raised against a human CD300C peptide using ARM Technology. A synthetic peptide of human CD300C is used for rabbit immunization.Customer or Abnova will decide on the preferred peptide sequence. (H00010871-K) - Products - Abnova
This Anti-Amyloid beta fibrils, clone M98, Rabbit Monoclonal Antibody is validated for use in Dot Blot and Western Blotting and Immunohistochemistry for the detection of Amyloid beta fibrils. - Find MSDS or SDS, a COA, data sheets and more information.
Polyethylene Glycol (PEG) rabbit monoclonal antibodies for pharmacokinetics and detection of PEGylated molecules in ELISA, WB, IHC..
Despite twenty years of scientific research, systemically administered radiolabelled MAbs have failed to demonstrate any significant therapeutic benefit. The fundamental barrier to success, in brain tumours, is the low percentage of the injected antibody taken up per gram of tumour (, 0.001%). This study builds on these experiences but utilises modern advances in stereotactic neurosurgery and computer graphics. It investigates the role of intralesional administration in an attempt to increase local uptake at first in experimental tumours and then in patients whose symptoms and eventual outcome are dictated by their local tumour. In the laboratory, the percentage of the injected activity taken up per gram of tumour (%ID/g) was three times greater following intralesional (IL) rather than systemic administration (Students t-test, p=0.012). Whereas, doses to the systemic organs were significantly lower following IL administration (Students t-test, p=0.041). Antibody specificity was found to be an ...
http://www.springbio.com - Spring Bioscience focuses on rabbit monoclonal antibodies for IHC. The goal from our inception has been to provide the reliability th...
alpha beta TCR Mouse anti-Human, FITC, Clone: WT31, eBioscience™ 25 tests; FITC alpha beta TCR Mouse anti-Human, FITC, Clone: WT31, eBioscience™ Primary...
... ; Antibody Type: Mouse Monoclonal antibody; Quality Control: Immunohistochemistry (IHC) positive to endogenous target protein.
Polyclonal antibodies are a pool of antibodies originating from different B cells in a host animal that recognize more than one epitope on the same protein or antigen. In contrast, a monoclonal antibody is an antibody originating from a single B cell in a host animal that recognizes only one epitope or binding site on a protein or other antigen. Polyclonal antibodies are usually purified from the serum of an immunized host animal such as a rabbit, chicken or goat. Whereas monoclonal antibodies are usually purified from cell culture media supernatant from the growth of a hybridoma cell line. Monoclonal antibodies are divalent but monospecific. Polyclonal antibodies are also divalent but consist of a pool of antibodies with multiple epitope specificities.. ...
This product contains sepharose beads coated with mouse anti-human IgG. Mouse anti-human IgG is affinity purified and conjugated to the beads at 1-1.5 mg/ml ratio. The beads may be used for purification of human IgG class of antibodies or proteins. The be
IL-17A Mouse anti-Human, Clone: eBio64CAP17, eBioscience™ 50 μg; Unconjugated IL-17A Mouse anti-Human, Clone: eBio64CAP17, eBioscience™ Primary...
Highlights: • A human monoclonal antibody against influenza virus was produced from a volunteer. • The antibody was generated from the PBMCs of the volunteer using the fusion method. • The antibody neutralized heterosubtypically group 1 influenza A viruses (H1 and H9). • The antibody targeted a novel epitope in globular head region of the hemagglutinin. • Sequences of the identified epitope are highly conserved among H1 and H9 subtypes. - Abstract: Most neutralizing antibodies elicited during influenza virus infection or by vaccination have a narrow spectrum because they usually target variable epitopes in the globular head region of hemagglutinin (HA). In this study, we describe a human monoclonal antibody (HuMAb), 5D7, that was prepared from the peripheral blood lymphocytes of a vaccinated volunteer using the fusion method. The HuMAb heterosubtypically neutralizes group 1 influenza A viruses, including seasonal H1N1, 2009 pandemic H1N1 (H1N1pdm) and avian H9N2, with a strong ...
CD36 Mouse anti-Human, Clone: eBioNL07 (NL07), eBioscience™ 100 μg; Unconjugated CD36 Mouse anti-Human, Clone: eBioNL07 (NL07), eBioscience™ Primary...
The present invention relates to anti-TNF Alpha antibodies preparation of a kind of stabilization and application thereof, specifically the preparation includes:(i) the anti-TNF Alpha antibodies of therapeutically effective amount;(ii) buffer system of 0.8 6.2mg/ml histidines is contained;(iii) osmotic pressure regulator;And (iv) surfactant, wherein, the pH of the preparation is 5.5 6.5.The preparation of the present invention can not only effectively reduce the chemical degradation reaction rate of anti-TNF alpha monoclonal antibodies, improve the chemical stability of antibody, extend the shelf life of product, and can eliminate or mitigate the injection site side reaction of patient, improve the medication comfort level of patient.In addition, the invention also discloses a kind of method of stabilization of antibodies and the purposes of said preparation.
CD68 Mouse anti-Human, PE-eFluor 610, Clone: eBioY1/82A (Y1/82A), eBioscience™ 25 tests; PE-eFluor 610 CD68 Mouse anti-Human, PE-eFluor 610, Clone: eBioY1/82A...
Ozato, K; Epstein, S L.; Henkart, P; Hansen, T H.; and Sachs, D H., "Studies on monoclonal antibodies to mouse mhc products." (1981). Subject Strain Bibliography 1981. 1766 ...
Monoclonal antibodies that target T cells offer an alternative to conventional immunosuppressive drugs in the management of autoimmune disease. Humanisation of such monoclonal antibodies makes their clinical use less likely to be prone to the risk of cross-species sensitisation than treatment with rodent antibodies. We describe humanised monoclonal antibody therapy in four patients with severe systemic vasculitis unresponsive to immunosuppressive drugs. Substantial and sustained benefit was seen in three of the four patients, although one of these three patients developed anti-idiotypic antibodies that had to be removed by plasma exchange.
The present invention relates to the monoclonal antibody e20 or a functional fragment thereof as a medicament for the therapeutic treatment and prevention of HCV infections. The e20 antibody is able to bind all of the known HCV genotypes and exhibits a strong neutralising activity against the virus, in particular towards genotypes 1a, 1b, 2a, and 4. A pharmaceutical composition is also described for the treatment or prevention of HCV infections, which comprises the monoclonal antibody e20 or a functional fragment thereof, and pharmaceutically acceptable excipients, carriers or diluents.
TY - JOUR. T1 - Establishment of neutralizing rat monoclonal antibodies for fibroblast growth factor-2. AU - Tanaka, Masako. AU - Yamaguchi, Maki. AU - Shiota, Masayuki. AU - Kawamoto, Yukiko. AU - Takahashi, Katsuyuki. AU - Inagaki, Azusa. AU - Osada-Oka, Mayuko. AU - Harada, Akihito. AU - Wanibuchi, Hideki. AU - Izumi, Yasukatsu. AU - Miura, Katsuyuki. AU - Iwao, Hiroshi. AU - Ohkawa, Yasuyuki. PY - 2014/8/1. Y1 - 2014/8/1. N2 - Fibroblast growth factor-2 (FGF-2) plays a critical role in endothelial survival, proliferation, and angiogenesis and is localized on the cell membrane by binding to heparan sulfate proteoglycans. Here we established a neutralizing monoclonal antibody, 1B9B9, against FGF-2 using the rat medial iliac lymph node method. 1B9B9 blocked the binding of FGF-2 to its receptor, inhibiting FGF-2-induced proliferation and corresponding downstream signaling in endothelial cells. Treatment of human umbilical vein endothelial cells with 1B9B9 reduced the basal phosphorylation levels ...
cd cd mouse monoclonal antibody | order cd cd mouse monoclonal antibody | How to use: cd cd mouse monoclonal antibody | support help for cd cd mouse monoclonal an
Hybridoma technology has been used successfully to generate monoclonal-antibody probes against protoplast membrane antigens. Hybridomas secreting monoclonal antibodies that either inhibit or stimulate a putative plasma-membrane marker enzyme, (K+ + Mg2+)-stimulated pH 6.5 ATPase, have been identified and cloned. The specificity of monoclonal-antibody probes on the activity of other phosphate-hydrolysing enzymes has also been examined. The production and identification of monospecific antibodies capable of immunoreacting with particular component proteins in a complex plant membrane mixture highlight the usefulness of hybridoma methodology for the enzymologist, especially since such monoclonal antibodies can be used in the purification of proteins by immunoaffinity techniques. ...
Analyses of the reactivity and patterns of synthesis of infected cell polypeptides (ICPs) specified by herpes simplex virus (HSV) 1 and 2 and by HSV-1 X HSV-2 recombinants indicated that monoclonal antibody H1183 reacted with HSV-1 alpha ICP0, whereas monoclonal antibody H1113 reacted with both HSV-1 and HSV-2 alpha ICP27. H1083 and H1113 and a monoclonal antibody to ICP4 (H640) similar to one previously described (D. K. Braun et al., J. Virol. 46:103-112.) were then used to study the properties of these alpha proteins. The results were as follows: alpha ICP0, ICP4, and ICP27 accumulated primarily in the nuclei of infected cells. ICP4 and ICP27 were poorly soluble in nondenaturing buffer solutions. ICP0 was considerably more soluble than ICP4 and ICP27. ICP0, ICP4, and ICP27 were readily partially purified by immunoaffinity chromatography from lysates of infected cells solubilized with denaturing agents such as sodium dodecyl sulfate. ICP0 and ICP27 were phosphorylated in cells overlaid with ...
Over recent decades, there has been a steady improvement in treatment outcome of patients with ALL. This progress is due to factors including intensification of chemotherapy and risk-adapted therapy, as well as better supportive care.1 As a result, cure rates now approach 90% and 40% for pediatric and adult ALL, respectively.2 While the risk of relapse is much lower in the pediatric population, both pediatric and adult patients face significantly inferior outcomes if the disease recurs. Less than one third of children and few adults with relapsed ALL survive, despite the use of aggressive salvage regimens and stem cell transplantation.3,4 Novel therapies are, therefore, needed that have both activity against ALL and a toxicity profile distinct from conventional chemotherapy. Targeted therapy using monoclonal antibodies such as rituximab and trastuzumab has become an integral part of standard treatment for certain malignancies.5,6 For ALL, there is pre-clinical and early clinical experience with ...
OUTLINE: This is a dose-escalation study of yttrium Y 90 monoclonal antibody m170 (Y90 MOAB m170).. Patients receive filgrastim (G-CSF) subcutaneously (SC) daily for 4 days prior to apheresis which continues daily for a maximum of 5 days. A minimum of 6 million CD34+ cells/kg must be harvested.. Patients receive oral cyclosporine every 12 hours on days -3 to 25. Patients receive unlabeled monoclonal antibody (MOAB) m170 IV followed by a tracer dose of indium In 111 MOAB m170 IV on day 0. On day 7, patients receive unlabeled MOAB m170 IV followed by Y90 MOAB m170 IV. Patients in cohorts 2-4 also receive paclitaxel IV over 3 hours on day 9.. If needed, patients undergo autologous peripheral blood stem cell transplantation on day 21 and receive G-CSF SC daily until blood counts recover.. Cohorts of 3-6 patients receive escalating doses of Y90 MOAB m170 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience ...
Monoclonal antibodies, shown here binding to a cell, are monospecific antibodies (these are antibodies that have an affinity for the same antigen) - mAB or moAb, as they are abbreviated, are the same because they are created by identical immune cells that are clones of a unique parent cell. Monoclonal antibodies are created to specifically bind to a substance so they can detect or purify that particular substance. In medications the non-proprietary drug name ends in -mab. Typically, monoclonal antibodies are produced by fusing myeloma cells with the spleen cells from a mouse and recently, as a result of advances, from rabbit B-cells. Monoclonals can be used as therapies for various serious diseases such as rheumatoid arthritis, multiple sclerosis and - Stock Image C009/4806
TY - JOUR. T1 - Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies directed against intracellular antigens. AU - Haisma, Hidde J.. AU - Pinedo, H. M.. AU - Silva, Carlos A.. AU - Boven, Epie. PY - 1992/9/18. Y1 - 1992/9/18. N2 - For investigations involving monoclonal antibodies (mAbs) against cellular antigens cell binding assays are routinely used to determine the immunoreactive fraction after radiolabeling. In general, surface antigens are targets for radioimmunodetection, but recent studies indicate that intracellular determinants may also prove useful for this purpose. Thus, there is a need to adapt the regular cell binding assay for use with antibodies directed against cytoplasmic antigens. Here we describ a fixation method which permits such mAbs to bind to cell surfaces as well as to intracellular determinants. Moreover, the procedure may be used for antigens that are sensitive to the commonly used aldehyde fixatives. The method is illustrated with two ...
Background: Identification and validation of a targeted therapy for triple-negative breast cancer (TNBC), that is, breast cancers negative for oestrogen receptors, progesterone receptors and HER2 amplification, is currently one of the most urgent problems in breast cancer treatment. EGFR is one of the best-validated driver genes for TNBC. EGFR is normally activated following the release of ligands such as TGF alpha, mediated by the two MMP-like proteases ADAM (a disintegrin and metalloproteinase)-10 and ADAM-17. The aim of this study was to investigate the antitumour effects of a monoclonal antibody against ADAM-17 on an in vitro model of TNBC. Methods: We investigated an inhibitory cross-domain humanised monoclonal antibody targeting both the catalytic domain and the cysteine-rich domain of ADAM17-D1(A12) in the HCC1937 and HCC1143 cell lines. Results: D1(A12) was found to significantly inhibit the release of TGFa, and to decrease downstream EGFR-dependent cell signalling. D1(A12) treatment ...
The global monoclonal antibody therapeutics market will be worth US$245.8 bn by 2024 from US$86.7 bn in 2015. During the forecast years of 2016 and 2024, the global monoclonal antibody therapeutics market is expected to rise at a CAGR of 12.6%.
Most adverse experiences (AEs) were transient grade 1 or 2 events occurring during the treatment period. Clinically significant myelosuppression was not observed; hematologic toxicity was generally mild and reversible. No patient developed human antichimeric antibodies after treatment. The type, frequency, and severity of AEs in this study were not apparently different from those reported in the phase III trial of rituximab. The overall response rate in 57 assessable patients was 40% (11% complete response and 30% partial responses). Median time to progression (TTP) in responders and median duration of response (DR) have not been reached, but Kaplan-Meier estimated medians are 17.8 months (range, 5.4+ to 26.6 months) and 16.3 months (range, 3.7+ to 25.1 months), respectively. These estimated medians are longer than the medians achieved in the patients prior course of rituximab (TTP and DR of 12.4 and 9.8 months, respectively, P: ,.1) and in a previously reported phase III trial (TTP in ...
Abbkine Scientific Co. Ltd is known for making quality life science products and tools and it recently announced the official launch of its new antibody - the Anti-Plant Actin Mouse Monoclonal Antibody (3T3).. The antibody otherwise known as AT3G12110 antibody is a Plant Actin Antibody, which is an essential component of cell cytoskeleton. The substance also plays a critical role in the streaming of cytoplasmic, determination of cell shape, cell division and extension growth.. The product is available in a liquid solution and hosted by mouse hence, Plant Actin Mouse mAb. The antibody is also a Recombinant Protein immunogen, with plant reactivity. The antibody like many of its other counterparts is affinity-purified from mouse ascites using specific immunogen by affinity-chromatography.. The Anti-Plant Actin Mouse Monoclonal Antibody (3T3) is made solely for research purpose and not intended for clinical or human use. It can also be stored for as long as one year at -20°C from date of ...
Read independent reviews on Thermo Scientific™ MAbPac™ SEC-1 Monoclonal Antibody Analysis Column from Thermo Fisher Scientific on SelectScience
Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies (mAb) to bind monospecifically to certain cells or proteins. The objective is that this treatment will stimulate the patients immune system to attack those cells. Alternatively, in radioimmunotherapy a radioactive dose localizes a target cell line, delivering lethal chemical doses. More recently antibodies have been used to bind to molecules involved in T-cell regulation to remove inhibitory pathways that block T-cell responses. This is known as immune checkpoint therapy. It is possible to create a mAb that is specific to almost any extracellular/cell surface target. Research and development is underway to create antibodies for diseases (such as rheumatoid arthritis, multiple sclerosis, Alzheimers disease, Ebola and different types of cancers). Immunoglobulin G (IgG) antibodies are large heterodimeric molecules, approximately 150 kDa and are composed of two kinds of polypeptide chain, called the heavy ...
Two-site immunometric assays for multideterminant antigens are described in which the antigen is reacted with an immobilized monoclonal antibody directed against one antigen determinant and a second monoclonal antibody that is directed against a distinct antigenic determinant and is of a different class or subclass than the immobilized monoclonal antibody. The second monoclonal antibody is labeled in direct versions of the assay and is reacted with a labeled antibody against it in indirect versions of the assay. The immobilizing medium and classes (subclasses) of the antibodies may be selected so as to reduce the likelihood of nonspecific binding enhance sensitivity and/or permit signal amplification.
There are 19 IL7R alpha / CD127 antibodies which are validated in multiple tissues with various applications, including IHC-P, ELISA, FCM, WB. There are 1 IL7R alpha / CD127 antibody for IHC-P, 10 IL7R alpha / CD127 antibody for ELISA, 9 IL7R alpha / CD127 antibody for FCM, 1 IL7R alpha / CD127 antibody for WB. Among all these IL7R alpha / CD127 antibodies, there are 7 anti-IL7R alpha / CD127 rabbit polyclonal antibodies , 1 anti-IL7R alpha / CD127 mouse monoclonal antibodies , 11 anti-IL7R alpha / CD127 rabbit monoclonal antibodies . All the IL7R alpha / CD127 anbodies are produced in house and all are in stock. IL7R alpha / CD127 antibody customerized service is available. ...
Blog on Mouse Anti-Human IgG2 (gamma 2 chain specific) secondary antibody product: The Mouse Anti-Human IgG2 (gamma 2 chain specific) n/a (Catalog #MBS674046) is a Secondary Antibody produ...
TY - JOUR. T1 - Enhanced HIV type 1 neutralization by human anti-glycoprotein 120 monoclonal antibodies in the presence of monoclonal antibodies to lymphocyte function-associated molecule 1. AU - Hioe, Catarina E.. AU - Hildreth, James. AU - Zolla-Pazner, Susan. PY - 1999/4/10. Y1 - 1999/4/10. N2 - Cellular adhesion receptor LFA-1 and its ICAM ligands are known to play a role in HIV infection. The presence of these molecules on virions and target cells promotes virus infectivity and has previously been shown to hinder virus neutralization by anti-HIV antibodies. To delineate the effect of these molecules on neutralization of HIV-1, human monoclonal antibodies (MAbs) to V3 and the CD4-binding domain (CD4bd) of gp120 were examined in the presence of anti-LFA-1 MAbs. When either of two anti-LFA-1 MAbs was present, higher levels of virus neutralization were achieved by both anti-V3 and anti- CD4bd MAbs. This effect was observed with primary HIV-1 isolates as well as with a laboratory-adapted strain. ...
Rabbit ,200 µg/ml of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.AB2, 36-3502
Monoclonal Antibody Production Service (Taiwan) Start Order Immediately by Completing the Inquiry Form.. I. Hybridoma fusion and screening service: 16 weeks (USD 5,100). II. MAP Immunogen monoclonal antibody production: Total 19 weeks (USD 5,800). III. LAE antigen monoclonal antibody production: Total 20 weeks (USD 6,600). IV. Optional Services. I Hybridoma fusion and screening service: 16 weeks. ...
Wuhan, China - 14th May, 2017 - DDDDK antibody is a new antibody produced by Abbkine Scientific Company Limited and the launch is set to revolutionize the science world especially in the area of research and investigation. Announcing the launch of the product, Abbkine Scientific reiterated the features and benefits of the Anti-DDDDK Tag Mouse Monoclonal Antibody (1B10), otherwise known as Flag antibody.. The monoclonal antibody is designed to be used for affinity chromatography and the subsequent separation of recombinant, over expressed protein from wild-type protein expressed by the host organism. This is in addition to being a polypeptide protein tag that can be added to a protein by using recombinant DNA technology.. Hosted in mouse, the antibody can also be used in the isolation of protein complexes that have multiple subunits.. Available in a liquid solution, the antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen, which is one of the ...
Our hybridoma bank contains over 20 murine hybridomas. Moreover, we have extensive experience in the purification and characterization of numerous murine monoclonal antibodies for in vitro and in vivo use. We have also generated monoclonal antibodies de novo by in vivo immunization and subsequent in vitro fusion of heterologous fusion partners from Chinese hamsters and rats, and produced IgA-secreting hybridomas de novo. Depending on the quantity of monoclonal antibodies required, hybridomas are propagated in either static flat tissue culture flasks or in roller bottle cultures. Monoclonal antibodies are purified by affinity column chromatography using protein G charged columns. The affinity purified monoclonal antibodies are dialyzed against deionized water, concentrated on a vacuum concentrator, resuspended in sterile PBS, and the protein concentration determined by BCA. The purity of the monoclonal antibodies is confirmed by western blotting with commercial anti-mouse IgG or IgM, antibodies, ...
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cel
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may
In a previous study employing conventional immunological marker analysis we found that 17% of high grade malignant lymphomas were devoid of cytoplasmic and membrane immunoglobulin and also sheep erythrocyte receptors. Cryostat sections from 24 of these cases (four of low grade and 20 of high grade malignancy) were stained with a panel of 30 monoclonal antibodies and six polyclonal antisera using a sensitive immunoperoxidase method. All tumours expressed the leucocyte common antigen (detected by monoclonal antibody 2D1) and all lacked epithelial cytokeratin (monoclonal antibody LE61), confirming their haematopoietic origin. All but one of the lymphomas expressed antigens characteristic of either B cells (17 cases) or T cells (six cases), while one case (morphologically a centroblastic lymphoma) had an unusual dual phenotype in which strong staining for T6 (marker of immature T cells) was associated with expression of the pan B lymphocyte antigens detectable with To15, anti-B1, anti-Leu12. This ...
The REA Control (I) antibody clone REA293 is a universal isotype control that can be used with all recombinant engineered antibodies (REAfinity™ Antibodies) that recognize intracellular antigens. REAfinity Antibodies have been engineered for their high specificity and contain human IgG1 parts for constant regions. Unspecific interactions of the fluorochrome can be controlled for with conjugated versions of clone REA293. For intracellular stainings however the isotype control staining should be combined with other negative controls (e.g. staining of unstimulated cells). - USA
Monoclonal human IgG1 antibody against human CD20 Anti-hCD20-hIgG1 features the constant region of the human IgG1 isotype and the variable region of rituximab. Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphoc
Monoclonal antibodies (Mabs), produced in the laboratory, are derived from the antibodies that the human body produces in the natural course to fight intruders that threaten health. The discovery of these antibodies have radically transformed our understanding of how diseases progress, and how they can be more quickly, accurately, and cheaply diagnosed, and thus substantially expanded the horizons of treatment for more than 50 major ailments. The importance of Mabs can be estimated from the fact that today a majority of the most commercially-successful drugs are Mab-derived, and Mab-drugs are projected to clock sales of US$125 billion annually by 2020.. Mabs in Cancer Treatment Cancer is unarguably one of the fields where monoclonal antibodies have had the strongest impact. The biggest advantage of Mabs is that they are able to avoid the healthy cells while specifically targeting the cancer cells. This translates to the patient experiencing fewer side effects than conventional radiotherapy or ...
In this study, we detail the generation and thorough characterization of three monoclonal antibodies that recognizes a peptide epitope associated with MHC class I. This type of antibody is known as a TCR-like monoclonal antibody (TCR-like mAb) in that it has the same specificity as a cytotoxic T-cell receptor. The three antibodies characterizd target epitopes derived from the EBV latent gene products LMP-1, LMP-2A, and EBNA-1. We demonstrate that these monoclonal antibodies exhibit specific high affinity binding to their respective HLA-A0201/peptide complexes and determined sites within peptides that affect antibody binding. We also investigate the effects of HLA-A02 subtypes and clinical peptide variants for antibody binding. These antibodies are used to visualize EBV latent epitopes in infected humanized NOD-scid IL2Rgammanull mice and NPC biopsies. In addition, we describe the quantity and expression hierarchy of these EBV latent epitopes in EBV infected HLA-A0201 positive tumor cell lines ...
TNF alpha antibody [MAB0856] (tumor necrosis factor) for Neut. Anti-TNF alpha mAb (GTX52438) is tested in Mouse samples. 100% Ab-Assurance.
The MD Anderson Monoclonal Antibody Core Facility provides custom monoclonal antibody production and purification to researchers at MD Anderson and beyond. Learn more.
The principle of cancer immunotherapy includes various methods of manipulations to influence immune responses against tumors in both humans and animals. This advanced technology of hybridoma production provided the necessary skills to efficiently produce highly specific monoclonal antibodies (mAb). Radioactively-tagged antibodies which are applied in radioimmunotherapy (RIT), can target adjacent cells and may not require immune function. This study highlights the mechanism and the effect of action of radioimmunotherapic agents, especially two applied agents including 90Y-ibritumomab tiuxetan and 131I-tositumomab that are approved by Food and Drug Administration (FDA) for treatment of some cancers.
7. The isolated monoclonal antibody of claim 2, wherein the epitope is a functional epitope.. 19. The isolated monoclonal antibody of claim 1 wherein the isolated monoclonal antibody binds to at least two of the following residues S153, 1154, P155, R194, D238, A239, 1369, S372, D374, C375, T377, C378, F379, V380, or S381 of PCSK9 listed in SEQ ID NO:3.. 29. A pharmaceutical composition comprising an isolated monoclonal antibody, wherein the isolated monoclonal antibody binds to at least two of the following residues S153, 1154, P155, R194, D238, A239, 1369, S372, D374, C375, T377, C378, F379, V380, or S381 of PCSK9 listed in SEQ ID NO:3 and blocks the binding of PCSK9 to LDLR by at least 80%. ...
PRIMARY OBJECTIVES:. I. To estimate the maximally tolerated dose (MTD) of 90Y-BC8-DOTA (anti-cluster of differentiation [CD]45) (yttrium-90 anti-CD45 monoclonal antibody BC8) that can be delivered prior to autologous stem cell transplantation for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL), T-cell NHL (T-NHL), and Hodgkin lymphoma (HL).. SECONDARY OBJECTIVES:. I. To optimize the protein dose (antibody [Ab]) to deliver a favorable biodistribution in the majority of patients.. II. To describe the impact of rituximab concentrations, B-cell depletion, and disease burden on CD20 and CD45 targeting.. III. To describe response rates and remission durations in relapsed B-NHL, T-NHL, and HL following administration of myeloablative doses of 90Y-BC8-DOTA prior to autologous stem cell transplant (ASCT).. IV. To assess the correlation of lymphoma biomarkers with outcomes.. OUTLINE: This is a dose-escalation study of yttrium-90 anti-CD45 monoclonal antibody BC8.. Patients receive ...
In vitro experiments using purified rat CD4+ T cells in primary and secondary mixed leukocyte cultures (MLC) have been carried out to explore the mechanism of inhibition of cell-mediated autoimmune disease in the rat by a nondepleting monoclonal antibody (mAb) to CD4. Previous work has shown that W3/25, a mouse anti-rat CD4 mAb of immunoglobulin G1 isotype, completely prevents the development of the paralysis associated with experimental allergic encephalomyelitis (EAE) in Lewis rats, but does so without eliminating the encephalitogenic T cells. The in vitro experiments described in this study have shown that when CD4+ T cells were activated in the presence of the anti-CD4 mAb in a primary MLC, the synthesis of interferon (IFN) gamma, but not interleukin (IL) 2, was completely inhibited. After secondary stimulation, now in the absence of the mAb, the synthesis of IL-4 and IL-13 mRNA was greatly enhanced compared with that observed from CD4+ T cells derived from primary cultures in which the mAb ...
ZytuxTM is a biosimilar product with the generic name of Rituximab. It is a genetically engineered human-mouse chimeric monoclonal antibody produced by Chinese Hamster Ovary (CHO) cells in suspension. It is a fusion of the light and heavy chain variable domains of a murine monoclonal anti-CD20 antibody and human kappa light-chain and gamma 1 heavy-chain constant regions. Rituximab is a chimeric monoclonal antibody against CD20 antigens presents on surface of lymphocyte cells. Rituximab binds to the target CD20 antigen via the variable murine regions, while the remainder of the antibody interacts with human immune-effector mechanisms to kill the target cells. Zytux™ is used for treatment of ...
Please register to see prices including your discount. Registration may take up to 24h. For guest orders the standard discount of your institution will apply and discounts are visible on the order confirmation.. ...
Integral Molecular, the industry leader in the discovery of monoclonal antibodies (MAbs) against membrane proteins, and Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced that they have entered into a collaboration on multiple undisclosed targets.
Monoclonal antibodies (MAbs) are made by identical immune cells and target one particular epitope by monovalent or monospecific affinity. The high affinity and selective binding of MAbs to epitopes in target antigens makes them highly potent tools for use in biochemistry, molecular biology and medicine. The first working method described for the isolation of monoclonal antibodies was hybridoma technology, based on forming hybrid cell lines (hybridomas) by fusing an antibody-producing B-cell with a myeloma cell [1]. The antibodies produced by a particular hybridoma clone share the same specificity. Thus, individual clones can be screened for the production of an antibody with the desired affinity. However, hybridoma technology has shortcomings: it takes a relatively long time (on the order of months) and has not been widely applied to organisms other than mice. Moreover, antibody sequence information is unavailable by this method. Thus, when a hybridoma-screened antibody is selected for further ...
CD197 (CCR7) Rat anti-Mouse, PE, Clone: 4B12, eBioscience™ 25 μg; PE CD197 (CCR7) Rat anti-Mouse, PE, Clone: 4B12, eBioscience™ Primary Antibodies CD151...
This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Monoclonal antibodies, such as ganitumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective with or without ganitumab in treating patients with newly diagnosed Ewing sarcoma ...
Cambridge Antibody Technology (CAT; Melbourn, Cambridgeshire), producer of fully human monoclonal antibodies using phage technology, has reported encouraging results from a phase Ib/IIa trial of an anti-TNFα monoclonal antibody for the treatment of rheumatoid arthritis. The antibody, when administered either intravenously or by self injection subcutaneously, reduced the severity of the arthritis for periods of up to six months and allowed repeated injections of the antibody without the development of immunological reactions. Phage technology is a radically different procedure from conventional monoclonal antibody manufacture and CAT currently holds a phage library containing in the region of 100 billion human antibodies. Using high throughput techniques, CAT can produce information on 1000 target peptide antigens each month and with a further proprietary technique, CAT then has methods to determine whether the targeted antigen is relevant to initiation or progression of the disease or is merely ...
Quality Mouse Monoclonal Antibodies manufacturers & suppliers - buy Purified Anti - Oxycodone Mouse Monoclonal Antibody 9.2mg/mL from China manufacturer.
Patent ?Recombinant monoclonal antibody with high affinity to the bacterial antigen of native and functional structure, a way of obtaining monoclonal antibodies and the application of recombinant monoclonal antibodies? ? submitted to the Patent Office of the Republic of Poland December 31, 2010, submission number P.393508 (Kapusta J, Kęsik-Brodacka M, Cecuda-Adamczewska V, Sączyńska V, Bociąg P, Brodzik R, Wolko B, Bartoszcze M, Płucienniczak G, Płucienniczak A ...
|p|Mouse Anti-Human IL-17F Clone B-G46 azide free Monoclonal Antibody.|/p| |p|This mAb can be used as a capture antibody in a human IL-17F sandwich Immunoassay to detect human IL-17F in combination with biotinylated human IL-17F Clone B-F60 biotinylated
Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM6 or MCM7. Monoclonal antibodies having the binding characteristics of an MCM6 or MCM7 antibody of the invention are further provided. Hybridoma cell lines that produce an MCM6 or MCM7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in practicing methods for diagnosing high-grade cervical disease comprising detecting overexpression of MCM6, MCM7, or both MCM6 and MCM7 in a cervical sample from a patient. Kits for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MCM6 or an MCM7 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention.
Gentaur molecular products has all kinds of products like :search , Ray Biotech \ Rat Anti-Mouse CD8, FITC-labeled \ 128-10052-2 for more molecular products just contact us
Monoclonal antibodies to prostatic cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies show specificity for a non-soluble, membrane associated, organ specific antigenic determinant limited in its distribution to normal and neoplastic, human prostate epithelial cells. The monoclonal antibodies, specifically 7E11-C5 monoclonal antibodies, may be suitable for diagnostic uses.
Monoclonal antibodies are substances produced in a lab that attach to certain proteins in the body (like a key in a lock). The antibodies can boost your bodys natural defenses against disease or can be used to kill cancer cells or slow the progress of a disease. Monoclonal antibodies are given through an intravenous...
Catalog Number: 87-KH011. Category: Monoclonal Antibody. Supplier: Sceti. To order Anti C mL Monoclonal Antibody Clone Cms from Sceti Contact [email protected] ...
LONDON, April 11, 2014 /PRNewswire/ --. ThioBridge™ linker to attach different payloads to a range of antibodies PolyTherics Limited ("PolyTherics"), a provider of technologies and services to enable the development of better biopharmaceuticals, today announced an extension to its ThioBridge™ antibody drug conjugate ("ADC") collaboration with MacroGenics Inc (NASDAQ: MGNX), a US biotechnology company developing innovative medicines utilizing its next generation antibody technologies.. PolyTherics has developed ThioBridge™ for site-specific conjugation of cytotoxic payloads to antibodies to provide more stable and less heterogeneous ADCs. MacroGenics has two antibody technology platforms, a Dual-Affinity Re-Targeting (DART™) bi-specific platform, in which a single recombinant molecule is able to target two different antigens, and Fc-optimized antibodies with improved effector function.. The collaboration was extended following the successful outcome of a research programme undertaken in ...
|p|Mouse Anti-Human IL-17F Clone B-F60 Biotin Detection mAb|/p| |p|This antibody can be used as the detection antibody in a Human IL-17F sandwich Immunoassay to detect Human IL-17F in combination with Human IL-17F capture antibody Clone B-G46 (Cat No |a
Co-developed by Amgen and Abgenix, panitumumab is an investigational product in a novel class of targeted cancer treatments called epidermal growth factor receptor (EGFr) inhibitors. Panitumumab (formerly ABX-EGF) is the first fully human monoclonal antibody directed against EGFr and is being evaluated as both a monotherapy and in combination with other agents for the treatment of various types of cancer, including colorectal, lung and kidney. Panitumumab was generated with Abgenixs XenoMouse(R)(1) technology, which creates a fully human monoclonal antibody that contains no murine (mouse) protein ...
Human immunodeficiency virus type 1 (HIV-1)-specific monoclonal antibodies with extraordinary potency and breadth have recently been described. In humanized mice, combinations of monoclonal antibodies have been shown to suppress viraemia, but the therapeutic potential of these monoclonal antibodies …
Monoclonal antibody (MAb) 4D5 was used to analyze the phosphorylation of p185HER2, the gene product of c-erbB-2/HER2, in SK-BR-3 cells. Culture in the continuous presence of 4D5 reduced the in vivo steady-state levels of p185HER2 phosphorylation by 80% in a dose-dependent manner, suggesting that MAb 4D5 may have interfered with the activation of phosphorylation of p185HER2. The observed MAb-mediated reduction of p185HER2 phosphorylation could not be completely accounted for by down-regulation. When cultures were grown under serum-free conditions, the steady-state levels of p185HER2 phosphorylation were reduced by 56%, and addition of 4D5 further inhibited phosphorylation to 20% of steady-state levels. With continuous exposure to increasing concentrations of newborn calf serum in these cultures, there was a linear increase in tyrosine-specific phosphorylation of p185HER2, reaching a 5.4-fold increase with 10% newborn calf serum. Phosphorylation of p185HER2 in the presence of newborn calf serum ...
In vitro evaluations of monoclonal antibody (mAb) in drug development can be both useful and challenging. Cytotoxicity and stability of protein therapeutic candidates at relevant concentrations in cell culture are of interest in pharmaceutical research. Bioanalytical strategies for mAb LC-MS based analysis involve using either intact or digested mAb. Our approach for determining the stability of a human mAb in cultures of primary rat hepatocytes was to use enzymatic protein digestion followed by LC-MS/MS quantitation of five surrogate peptides...
... Monoclon Antib Immunodiagn Immunother. 2015 Aug;34(4):251-6 Authors: Xu H, Wei D, Xue J, Hu L Abstract DAB2 interactive protein (DAB2IP), also known as ASK1-interacting protein-1 (AIP1), a novel member of the RasGTPase-activating protein family, plays a key role in tumor suppression during cancer progression and is highly expre...